Vanguard Group Inc Praxis Precision Medicines, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $2.78 Million - $5.47 Million	3,199,541 Added 135.31%	5,564,114 $9.51 Million
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.18 $186,477 - $265,112	224,672 Added 10.5%	2,364,573 $2.72 Million
Q1 2023 May 15, 2023	BUY	$0.8 - $4.98 $282,884 - $1.76 Million	353,605 Added 19.8%	2,139,901 $1.73 Million
Q4 2022 Feb 10, 2023	SELL	$1.88 - $2.49 $33,947 - $44,961	-18,057 Reduced 1.0%	1,786,296 $4.25 Million
Q3 2022 Nov 14, 2022	SELL	$2.5 - $4.77 $1.84 Million - $3.52 Million	-736,945 Reduced 29.0%	1,804,353 $4.1 Million

Q2 2022 Aug 12, 2022	SELL	$1.75 - $11.34 $1.37 Million - $8.85 Million	-780,842 Reduced 23.5%	2,541,298 $6.23 Million
Q1 2022 May 13, 2022	BUY	$10.21 - $20.29 $303,206 - $602,552	29,697 Added 0.9%	3,322,140 $33.9 Million
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $1.42 Million - $1.94 Million	84,518 Added 2.63%	3,292,443 $64.9 Million
Q3 2021 Nov 12, 2021	BUY	$13.15 - $22.56 $8.68 Million - $14.9 Million	660,172 Added 25.91%	3,207,925 $59.3 Million
Q2 2021 Aug 13, 2021	BUY	$18.28 - $33.05 $46.6 Million - $84.2 Million	2,547,753 New	2,547,753 $46.6 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $1.79B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.